The cyclin D-CDK4/6-INK4-Rb pathway is frequently deregulated in breast cancer via CCND1 (cyclin D1) amplification (29–58%), CDK4 (14–25%) and CDK6 amplification [18], p16 loss (49%) [19], and TP53 inactivation (12–84%) [18]. The gene discussed is CCND1; the disease is breast cancer.